EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Cutaneous Hypersensitivity Reactions to Immune Checkpoint Inhibitors

Ryan Storgard, Alina Markova

The Journal of Allergy and Clinical Immunology: In Practice · 2024-05 · 12 (5) · 1132-1136

DOI: 10.1016/j.jaip.2024.03.034 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift The Journal of Allergy and Clinical Immunology: In Practice, 2024-05. Verfasst von Ryan Storgard und 1 weiteren Autor:innen. Beteiligte Einrichtung: Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY. Electronic address: rcs4002@med.cornell.edu. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 40 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The introduction of immune checkpoint inhibitors (ICIs) has transformed the management of various malignancies. Alongside their therapeutic success, the widespread application of ICIs has unveiled a spectrum of immune-related adverse events (irAEs), most often affecting the skin. Cutaneous irAEs (cirAEs) encompass a range from common morbilliform and lichenoid rashes to more severe conditions such as bullous dermatoses and psoriasiform eruptions, each presenting distinct clinical challenges. Moreover, less common but clinically severe cutaneous reactions like toxic epidermal necrolysis have also been observed. cirAEs are frequently observed, with an incidence ranging from 37% to 70% for anti-cytotoxic T lymphocyte-associated antigen-4 antibodies and 17% to 40% for anti- programmed death-1/anti-programmed death ligand-1 antibodies. Recognizing the critical need for effective therapeutic strategies, this review carefully examines current approaches and guidelines for managing cirAEs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immune Checkpoint InhibitorsHumansDrug EruptionsNeoplasmsSkinStevens-Johnson Syndrome

Stichwörter der Autor:innen

Cutaneous adverse eventsDermatologic adverse eventsImmune checkpoint inhibitorsImmune-related adverse events

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY. Electronic address: rcs4002@med.cornell.edu.
  • Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.

Zitieren

APA

Storgard, R., & Markova, A. (2024). Cutaneous Hypersensitivity Reactions to Immune Checkpoint Inhibitors. The Journal of Allergy and Clinical Immunology: In Practice, 12(5), 1132-1136. https://doi.org/10.1016/j.jaip.2024.03.034

Vancouver

Storgard R, Markova A. Cutaneous Hypersensitivity Reactions to Immune Checkpoint Inhibitors. The Journal of Allergy and Clinical Immunology: In Practice. 2024;12(5):1132-1136. doi:10.1016/j.jaip.2024.03.034

BibTeX
@article{Storgard2024,
  author = {Storgard, Ryan and Markova, Alina},
  title = {Cutaneous Hypersensitivity Reactions to Immune Checkpoint Inhibitors},
  journal = {The Journal of Allergy and Clinical Immunology: In Practice},
  year = {2024},
  volume = {12},
  number = {5},
  pages = {1132--1136},
  doi = {10.1016/j.jaip.2024.03.034}
}
Kostenlos starten →